secwatch.observer — SEC 8-K summary
======================================

Issuer:     Telomir Pharmaceuticals, Inc. (TELO)
CIK:        0001971532
Form:       8-K
Filed at:   2025-05-21T23:59:59+00:00
Accession:  0001641172-25-011938
Event type: leadership
Sentiment:  neutral
Materiality: 0.45
Item codes: 1.01, 5.02, 3.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Telomir Pharmaceuticals appoints Alan Weichselbaum as CFO; prior CFO Michelle Yanez departs
--------------------------------------------------------------------------------

- Michelle Yanez and Telomir mutually agreed to her resignation as CFO, Treasurer, Secretary effective May 16, 2025; no disagreement.
- Alan Weichselbaum appointed CFO starting May 19, 2025; part-time role (30 hrs/week), salary $60,000/year.
- Weichselbaum receives 50,000 stock options vesting over 12 months (25k at 6 months, 25k at 12 months).
- Weichselbaum concurrently serves as CFO of MIRA Pharmaceuticals and CEO of Wexus Group.
- Employment is at-will, remote from New York, subject to background/reference check.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1971532/000164117225011938/0001641172-25-011938-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1971532/000164117225011938/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001641172-25-011938

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer